-
Posted by
Two Blokes Jul 21 -
Filed in
Stock
-
6 views
Imaging Biometrics Ltd (LSE:IBAI, OTCQB:IQAIF) has announced a soft close to its phase I trial of oral gallium maltolate for adults with relapsed or treatment-resistant glioblastoma, signalling that the study has reached sufficient enrollment to progress to the next stage. The company said no new patients will be recruited at this point, but the trial remains active for those already participating.
